Veru pivots sabizabulin to daraxonrasib-resistant pancreatic cancer; drops cardiovascular program

VERU INC.

Sabizabulin showed potent activity (IC50=18.2nM) in daraxonrasib-resistant KRAS pancreatic cancer cells; resistance index 0.25 vs 68 for daraxonrasib.
Company plans Phase 2b trial in daraxonrasib-resistant metastatic pancreatic cancer; pre-IND meeting with FDA in Q4 2026.
Veru will no longer explore sabizabulin for atherosclerotic cardiovascular disease inflammation; IP protection until 2043.
Prior Phase 1b/2 data in 80 prostate cancer patients: median rPFS 11.4 months, ORR 20.7% at 63 mg daily dosing.
Enobosarm obesity program on track: PLATEAU Phase 2b fully enrolled, interim analysis Q1 2027; Novo Nordisk supply deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.